Sun Pharmaceutical Industries faces US anti-trust suit
The petitioner claims Sun Pharma had allegedly manipulated US FDA rules
New Delhi: Sun Pharmaceutical Industries, India’s largest drug seller by sales, on Friday said it is reviewing a complaint filed against it and its subsidiaries by Meijer Inc alleging anti-trust and other violations in connection with Ranbaxy securing market exclusivity for certain products.
“Meijer Inc filed a purported class action complaint on May 12, 2015 against the company and its certain subsidiaries, alleging antitrust and RICO Act violations in connection with Ranbaxy securing market exclusivity as part of the FDA’s approval for certain products,” Sun Pharma said. The company is reviewing the complaint and has “no comments at this time,” it added.
As per reports, Ranbaxy Laboratories has been sued in the US District Court in Massachusetts for allegedly manipulating US FDA rules to keep generic drugs of other companies out of market place. Sun Pharma has acquired Ranbaxy last year.
Michigan retailer Meijer Inc is seeking to represent buyers of Roche Holding AG’s Valcyte, which treats a virus afflicting transplant patients, and Novartis AG’s blood-pressure drug Diovan, as per the reports.